Renal

July 2015 Vol. 10 No. 7

Author: Susan M. Dirkes, BSN, MSA, CCRN

When you arrive for your afternoon shift, you receive report from the day-shift nurse. He states he just admitted Marc Stevens, age 78, after a colostomy takedown. He reports that the patient’s blood pressure (BP) decreased in the operating room several times, with systolic BP dropping to 70 . . .

March 2012 Vol. 7 No. 3

Author: Wendy J. Silverstein, MA, RN, ACNS-BC, CPHQ

On March 29, the U.S. Food and Drug Administration (FDA) approved Omontys (peginesatide) to treat anemia in adult patients who had chronic kidney disease and are on dialysis. Read more . . .

November 2013 Vol. 8 No. 11

Author: Amy Garcia, MSN, RN, and Kate Nell, MA, RN

Researchers in England found that increased prescribing of ACE inhibitors and angiotensin-receptor antagonists (ARAs) was associated with the increased rates of hospital admissions for acute kidney injury. Read more . . .

November 2013 Vol. 8 No. 11

Author: Amy Garcia, MSN, RN, and Kate Nell, MA, RN

Lowering blood pressure (BP) is a highly effective and affordable way to prevent cardiovascular events like heart attack and stroke among people with chronic kidney disease, according to a meta-analysis published in the British Medical Journal. Read more and read the study abstract . . .

October 2013 Vol. 8 No. 10

Author: Nanette Yragui, PhD; Barbara Silverstein, MSN, RN, PhD, MPH; and Whitney Johnson, MPH

On Oct. 10, the U.S. Food and Drug Administration (FDA) approved Liposorber LA-15 System to treat pediatric patients with primary focal segmental glomerulosclerosis (FSGS) either before transplant, or after renal transplantation when there is recurrence of FSGS. Read more . . .

February 2013 Vol. 8 No. 2

Author: Lynne Hancock RN, MSN. NE-BC, and Diane Hanley MS, RN-BC, EJD

On Jan. 25, 2013, the U.S. Food and Drug Administration notified healthcare professionals of significant liver injury associated with the use of Samsca in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). In a double-blind, 3-year, placebo-controlled trial in about 1400 patients with ADPKD and its . . .

November 2012 Vol.7 No. 11

Author: Christina L. Dobson, MSN, RN, FNP-C

The OPTN/UNOS Board of Directors has approved policies aimed at creating greater consistency in the medical and psychosocial evaluation and informed consent processes for living kidney donors and increase the level of clinical information reported on post-transplant outcomes for these donors. The policies specify a minimum set of . . .

November 2012 Vol.7 No. 11

Author: Stephanie Barker, BSN, RN

A drug addict goes to a respite-care facility to die after finding treatment for kidney disease too difficult.

October 2012 Vol. 7 No. 10

Author: Rose O. Sherman, EdD, RN, NEA-BC, FAAN

According to a study in the American Journal of Transplantation, 31% of kidney transplant patients are readmitted to the hospital within 30 days of discharge. Factors increasing the likelihood of readmission include older age, African American race, and various comorbidities. Read more . . .